| Literature DB >> 10932251 |
V Sharma1, S Sharma, K Hoener zu Bentrup, J D McKinney, D G Russell, W R Jacobs, J C Sacchettini.
Abstract
Isocitrate lyase (ICL) plays a pivotal role in the persistence of Mycobacterium tuberculosis in mice by sustaining intracellular infection in inflammatory macrophages. The enzyme allows net carbon gain by diverting acetyl-CoA from beta-oxidation of fatty acids into the glyoxylate shunt pathway. Given its potential as a drug target against persistent infections, we solved its structure without ligand and in complex with two inhibitors. Covalent modification of an active site residue, Cys 191, by the inhibitor 3-bromopyruvate traps the enzyme in a catalytic conformation with the active site completely inaccessible to solvent. The structure of a C191S mutant of the enzyme with the inhibitor 3-nitropropionate provides further insight into the reaction mechanism.Entities:
Mesh:
Substances:
Year: 2000 PMID: 10932251 DOI: 10.1038/77964
Source DB: PubMed Journal: Nat Struct Biol ISSN: 1072-8368